PT1246925E - Bi - ou oligómero de um di -, tri-, quattro - ou pentâmero de proteínas de fusão recombinantes - Google Patents

Bi - ou oligómero de um di -, tri-, quattro - ou pentâmero de proteínas de fusão recombinantes Download PDF

Info

Publication number
PT1246925E
PT1246925E PT00987425T PT00987425T PT1246925E PT 1246925 E PT1246925 E PT 1246925E PT 00987425 T PT00987425 T PT 00987425T PT 00987425 T PT00987425 T PT 00987425T PT 1246925 E PT1246925 E PT 1246925E
Authority
PT
Portugal
Prior art keywords
fragment
protein
fusion proteins
recombinant fusion
collectin
Prior art date
Application number
PT00987425T
Other languages
English (en)
Inventor
Juerg Tschopp
Pascal Schneider
Nils Holler
Original Assignee
Topotarget Switzerland Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7935052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1246925(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Topotarget Switzerland Sa filed Critical Topotarget Switzerland Sa
Publication of PT1246925E publication Critical patent/PT1246925E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
PT00987425T 1999-12-30 2000-12-20 Bi - ou oligómero de um di -, tri-, quattro - ou pentâmero de proteínas de fusão recombinantes PT1246925E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19963859A DE19963859A1 (de) 1999-12-30 1999-12-30 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen

Publications (1)

Publication Number Publication Date
PT1246925E true PT1246925E (pt) 2008-08-11

Family

ID=7935052

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00987425T PT1246925E (pt) 1999-12-30 2000-12-20 Bi - ou oligómero de um di -, tri-, quattro - ou pentâmero de proteínas de fusão recombinantes

Country Status (19)

Country Link
US (6) US7385032B2 (pt)
EP (2) EP1246925B1 (pt)
JP (1) JP5031165B2 (pt)
KR (1) KR100767980B1 (pt)
CN (1) CN100385002C (pt)
AT (1) ATE397076T1 (pt)
AU (1) AU783833B2 (pt)
BR (1) BRPI0017054B1 (pt)
CA (1) CA2395632C (pt)
CY (1) CY1108195T1 (pt)
DE (2) DE19963859A1 (pt)
DK (1) DK1246925T3 (pt)
ES (1) ES2307550T3 (pt)
HU (1) HU229204B1 (pt)
IL (2) IL150215A0 (pt)
PL (1) PL204277B1 (pt)
PT (1) PT1246925E (pt)
WO (1) WO2001049866A1 (pt)
ZA (1) ZA200205069B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
EP1365027A4 (en) * 2000-05-26 2005-06-22 Mochida Pharm Co Ltd FUSION PROTEINS AS FAS-LIGAND
GB0015426D0 (en) * 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
DE60232577D1 (de) * 2001-01-18 2009-07-23 Vlaams Interuniv Inst Biotech Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
DE10122140A1 (de) * 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
DK1456651T3 (da) 2001-11-30 2008-09-01 Ca Nat Research Council Selvsamlende molekyler
US7736657B2 (en) 2002-02-10 2010-06-15 Apoxis S.A. Fusion constructs containing active sections on TNF ligands
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
AU2002351811A1 (en) * 2002-05-08 2003-11-11 Apoxis S.A. Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the same
FR2840307B1 (fr) * 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CA2503697A1 (en) * 2002-10-29 2004-05-13 Borean Pharma A/S Trimeric binding proteins for trimeric cytokines
CA2520254A1 (en) * 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
WO2004101740A2 (en) 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Clotting factor-fc chimeric proteins to treat hemophilia
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050143297A1 (en) * 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
EP1481686A1 (en) * 2003-05-26 2004-12-01 Apoxis SA Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
BRPI0516723A (pt) * 2004-10-01 2008-09-16 Apoxis Sa métodos para a purga ex-vivo de células em transplante autólogo, para preparação de células coletadas substancialmente isentas de células malignas, células coletadas, e, método para o transplante autólogo de células
FR2879202B1 (fr) * 2004-12-15 2007-02-23 Centre Nat Rech Scient Cnrse Nouveaux ligands multimeriques de cd40, leur procede de preparation et leur utilisation pour la preparation de medicaments
WO2006077232A2 (en) * 2005-01-20 2006-07-27 Apoxis Sa Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
CA2636424A1 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
JP6002903B2 (ja) 2007-07-10 2016-10-05 アポゲニクス アーゲー Ｔｎｆスーパーファミリーコレクチン融合タンパク質
PL2604693T3 (pl) * 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
EP2382236B1 (en) 2009-01-09 2016-08-17 Apogenix AG Fusion proteins forming trimers
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
CN102612525A (zh) 2009-06-09 2012-07-25 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
SG178125A1 (en) 2009-08-03 2012-03-29 Univ Miami Method for in vivo expansion of t regulatory cells
EP2518078B1 (en) * 2009-12-15 2020-05-20 Choe, Muhyeon Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
WO2012040101A1 (en) 2010-09-21 2012-03-29 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
EP2681245B1 (en) * 2011-03-03 2018-05-09 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2013121368A2 (en) * 2012-02-15 2013-08-22 Biocon Limited A process for detection and optional quantification of an analyte
US9562077B2 (en) * 2012-07-11 2017-02-07 Children's Hospital Medical Center Protein complex system for increased immunogenicity and functionality, and methods making and use
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
KR20150136047A (ko) 2013-01-09 2015-12-04 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
WO2014145355A1 (en) 2013-03-15 2014-09-18 Stone Geoffrey W Composition comprised of antigen linked to a tnf superfamily ligand
WO2014179494A1 (en) 2013-04-30 2014-11-06 Colorado State University Research Foundation Sensors and assays for ubiquitin or ubiquitin-like proteins
CA2917721C (en) * 2013-05-30 2023-03-14 Muhyeon Choe Super-complex formed by cross-binding between complexes of repeating chain and monomer and use thereof
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
CN104299540A (zh) * 2013-07-15 2015-01-21 驰众信息技术（上海）有限公司 广告互动播放系统及其广告机终端
NO2776305T3 (pt) 2014-04-23 2018-01-27
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
CN104356233B (zh) * 2014-10-11 2017-09-29 中国科学院微生物研究所 一种人热休克蛋白gp96的scFv抗体及其制备方法与应用
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
IL284430B2 (en) 2015-01-20 2024-04-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
ES2754432T3 (es) 2015-05-04 2020-04-17 Apogenix Ag Proteínas agonistas de receptor CD40 de cadena sencilla
TW201718632A (zh) * 2015-08-12 2017-06-01 梅迪繆思有限公司 Ｇｉｔｒｌ融合蛋白及其用途
WO2017068180A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
CN108473549A (zh) 2015-10-23 2018-08-31 阿珀吉科吉尼科斯股份公司 单链gitr受体激动剂蛋白
EP3368558A1 (en) 2015-10-28 2018-09-05 Apogenix AG Single-chain tl1a receptor agonist proteins
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
AU2017245143B2 (en) 2016-03-30 2024-01-11 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
CN109843931A (zh) 2016-08-11 2019-06-04 昆士兰医学研究所理事会 免疫调节化合物
EP3559239A1 (en) * 2016-12-22 2019-10-30 Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK) Oligomeric vaccines from plants by s-tag-s-protein fusions
JP2020515531A (ja) 2017-03-28 2020-05-28 チルドレンズ ホスピタル メディカル センター ノロウイルスｓ粒子ベースのワクチンならびにその作製および使用方法
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
CN112552415B (zh) * 2021-02-22 2021-06-22 北京百普赛斯生物科技股份有限公司 B淋巴细胞刺激因子十二聚体及其制备方法与应用
EP4347665A1 (en) * 2021-05-27 2024-04-10 Beijing Anxinhuaide Biotech. Co., Ltd. A super-trail molecule comprising two trail trimers
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859330A (en) * 1989-12-12 1999-01-12 Epitope, Inc. Regulated expression of heterologous genes in plants and transgenic fruit with a modified ripening phenotype
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
JP3762220B2 (ja) * 1997-07-18 2006-04-05 ザイモジェネティクス，インコーポレイティド 脂肪細胞特異的タンパク質分子
JP4057127B2 (ja) * 1998-02-19 2008-03-05 セイコーエプソン株式会社 アクティブマトリックス基板及びアクティブマトリックス基板の製造方法並びに液晶装置
IL137706A0 (en) * 1998-02-19 2001-10-31 Harvard College Mhc fusion proteins and conjugates
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
MXPA01012092A (es) * 1999-05-27 2002-07-22 Zymogenetics Inc Proteina homologa zacrp5 relacionada al complemento de adipocitos.
ATE316982T1 (de) * 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen

Also Published As

Publication number Publication date
CN100385002C (zh) 2008-04-30
EP1985706A3 (de) 2009-05-13
CN1526020A (zh) 2004-09-01
BRPI0017054B1 (pt) 2017-04-04
ATE397076T1 (de) 2008-06-15
EP1985706A2 (de) 2008-10-29
DE19963859A1 (de) 2001-07-12
WO2001049866A1 (de) 2001-07-12
EP1246925B1 (de) 2008-05-28
IL150215A (en) 2008-11-26
CY1108195T1 (el) 2014-02-12
ZA200205069B (en) 2004-03-24
DK1246925T3 (da) 2008-09-01
US20030053984A1 (en) 2003-03-20
CA2395632C (en) 2012-08-28
IL150215A0 (en) 2002-12-01
BR0017054A (pt) 2003-01-07
AU2367301A (en) 2001-07-16
US20040235117A1 (en) 2004-11-25
PL358456A1 (en) 2004-08-09
EP1246925A1 (de) 2002-10-09
JP5031165B2 (ja) 2012-09-19
AU783833B2 (en) 2005-12-08
HU229204B1 (hu) 2013-09-30
KR100767980B1 (ko) 2007-10-18
US20120009211A1 (en) 2012-01-12
ES2307550T3 (es) 2008-12-01
US20150004129A1 (en) 2015-01-01
PL204277B1 (pl) 2009-12-31
US20090053252A1 (en) 2009-02-26
US7385032B2 (en) 2008-06-10
US20130202552A1 (en) 2013-08-08
KR20020089319A (ko) 2002-11-29
DE50015185D1 (de) 2008-07-10
HUP0203628A2 (en) 2003-02-28
CA2395632A1 (en) 2001-07-12
JP2003518949A (ja) 2003-06-17

Similar Documents

Publication Publication Date Title
IL150215A0 (en) Di-or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
Waterfield et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
Mehta et al. Affinity and kinetic analysis of P-selectin binding to P-selectin glycoprotein ligand-1
NZ502392A (en) Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
ATE168415T1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
IL136621A0 (en) Cell surface glycoproteins associated with human b cell lymphomas
NO20000934L (no) Adipocyttspesifikke proteinhomologer
ATE259419T1 (de) Humanes cyr61, ein signalmolekül der extrazellulaeren matrix
ATE271129T1 (de) Isoliertes p27 protein und nukleinsäure dafür kodierend
CA2318482A1 (en) Il-18 receptors
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
NO20000215L (no) Adipocyttspesifikke proteinhomologer
DE10075011I2 (de) Rezeptoren für Tumornekrosisfaktor-alpha und-beta.
PT1015586E (pt) Homologos de ligandos do receptor tirosina-quinase tie
DE69738670D1 (de) Verfahren zur oligomerisation von peptiden
ATE335818T1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
Kumagai et al. Disulfide-bonding between Drosophila laminin β and γ chains is essential for α chain to form αβγ trimer
Krautwald et al. Bacterially expressed murine CSF-1 possesses agonistic activity in its monomeric form
WO1990007000A3 (en) Nucleotides encoding human b1, 4-galactosyltransferase and uses thereof
DE68918519D1 (de) DNA, welche für ein antikoagulierendes Polypeptid kodiert.
IL138585A0 (en) Vertebrate batched -2 protein
WO2001000664A3 (en) Secreted alpha-helical protein-36
Ji et al. Macromolecular affinity labeling
Alexenko et al. Mapping of an epitope of human leukocyte alpha interferon A which is recognized by the murine monoclonal antibody NK2.
Niimi et al. Distinct roles of mouse laminin β1 long arm domains for α1β1γ1 trimer formation